Component
Erythrocyte FMN concentration
Measured process or biological entity; consult each linked claim for the experimental scope.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
Where it participates (unsigned role)
In 46 randomized older adults, supplementation increased plasma riboflavin by 83% and erythrocyte FMN by 87%; measured markers other than plasma FAD responded significantly.
Experimental context and source evidence
- availability_state
- biomarker_context Imported condition classification; unverified.
- experimental_model
- 124 healthy older adults, mean age 69; 46 with EGRAC >=1.20 randomized equally to riboflavin or placebo.
- exposure
- 1.6 mg/day riboflavin versus placebo for 12 weeks; HPLC plasma/red-cell vitamer measurements.
- limitations
- Older adults selected by EGRAC; percentages are study responses, not diagnostic thresholds or predicted individual gains.
- nutrient_topic
- Riboflavin research collection; topical membership is not evidence of a direct dietary effect. · Riboflavin (vitamin B2)
- organism
- Homo sapiens
- plain_language
- Blood B2 comes in several forms, and they do not all respond equally to intake.
- primary_references
- [b2-hustad2002] Riboflavin, flavin mononucleotide, and flavin adenine dinucleotide in human plasma and erythrocytes at baseline and after low-dose riboflavin supplementation (2002). https://pubmed.ncbi.nlm.nih.gov/12194936/ DOI: 10.1093/clinchem/48.9.1571
- tissue_or_cell_type
- Human clinical setting
- trigger_kind
- biomarker_context Imported condition classification; unverified.
Riboflavin: mechanisms, deficiency and nutrient interactions (2026-09-17) · lines 1617–1627
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · 124 healthy older adults, mean age 69; 46 with EGRAC >=1.20 randomized equally to riboflavin or placebo. · source_derived_draft · unverified_draft
### b2-blood-vitamer-response In 46 randomized older adults, supplementation increased plasma riboflavin by 83% and erythrocyte FMN by 87%; measured markers other than plasma FAD responded significantly. Condition category: biomarker_context nutrient_topic: Riboflavin research collection; topical membership is not evidence of a direct dietary effect. plain_language: Blood B2 comes in several forms, and they do not all respond equally to intake. organism: Homo sapiens tissue_or_cell_type: Human clinical setting experimental_model: 124 healthy older adults, mean age 69; 46 with EGRAC >=1.20 randomized equally to riboflavin or placebo. limitations: Older adults selected by EGRAC; percentages are study responses, not diagnostic thresholds or predicted individual gains. exposure: 1.6 mg/day riboflavin versus placebo for 12 weeks; HPLC plasma/red-cell vitamer measurements. [b2-hustad2002] Riboflavin, flavin mononucleotide, and flavin adenine dinucleotide in human plasma and erythrocytes at baseline and after low-dose riboflavin supplementation (2002). https://pubmed.ncbi.nlm.nih.gov/12194936/ DOI: 10.1093/clinchem/48.9.1571
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.